In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report). The ...

Sei Investments Co. trimmed its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 15.4% in ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...

KLP Kapitalforvaltning AS acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) during the 4th quarter, according to its most recent filing with the Securities and ...

In trading on Tuesday, shares of Ultragenyx Pharmaceutical Inc (Symbol: RARE) entered into oversold territory, hitting an RSI reading of 27.3, after changing hands as low as $33.69 per share.

In the preceding three months, 10 analysts have released ratings for Ultragenyx Pharmaceutical RARE, presenting a wide array of perspectives from bullish to bearish. The following table provides a ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) tops our list for being one of the best genomic stocks. It focuses on developing and commercializing treatments for genetic diseases. Its product ...